India Pharma Outlook Team | Wednesday, 06 May 2026
Ajanta Pharma reported strong growth in its Ajanta Pharma Q4 results, with both domestic and global businesses driving performance for the quarter ended March 31, 2026.
Revenue from operations rose 21 percent year-on-year to Rs 1,422 crore, compared to Rs 1,170 crore in the same period last year. Profit after tax climbed 18 percent to Rs 267 crore, while EBITDA came in at Rs 333 crore, translating to a margin of 23 percent.
The company noted that the quarter was impacted by a mark-to-market forex loss of Rs 42 crore. Excluding this, adjusted EBITDA grew 26 percent to Rs 375 crore, with margins improving to 26 percent, highlighting underlying operational strength.
Also Read: Drugmakers Head Into Uneven Q4 as Margins Come Under Strain
For the full financial year FY26, Ajanta Pharma Q4 results capped a solid year. Revenue increased 17 percent to Rs 5,453 crore, while PAT rose 15 percent to Rs 1,056 crore. EBITDA stood at Rs 1,395 crore, and adjusted EBITDA reached Rs 1,498 crore after factoring out forex losses. The company also reported healthy returns, with ROCE at 33 percent and RONW at 25 percent.
A key growth driver remained its US generics segment, which surged 56 percent in Q4 revenue to Rs 505 crore. For the full year, this segment grew 49 percent to Rs 1,557 crore. Meanwhile, branded generics across India, Asia, and Africa contributed Rs 859 crore during the quarter.
Ajanta Pharma continued to invest in future growth, allocating around 5 percent of its FY26 revenue to research and development. The pipeline remains active, with multiple ANDA filings awaiting approval from the US FDA.
The company also informed exchanges that the audio recording of its Q4 FY26 earnings call held on May 5, 2026, has been uploaded on its website in line with regulatory requirements.
.jpg)
.jpg)
